WGSNasdaqServices-Health ServicesFiscal year ends December 31
GeneDx Holdings Corp.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$66.29+2.68 (+4.21%)
Close on Oct 19, 2026
- Market cap
- $1.97B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Gross margin
69.7%+67.5 pts over 5 years
Operating margin
-3.1%+131.9 pts over 5 years
Net margin
-4.9%+129.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +40.0% | +22.1% | +19.0% | – | |
| Gross profit | +53.4% | – | +136.5% | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 115.3% | -7.6% | |
| Return on assets | – | – | -4.5% | |
| Current ratio | – | 2.37 | 2.46 | |
| Debt to equity | – | -0.06 | 0.17 | |
| Net debt to EBITDA | – | 0.38× | 15.04× | |
| Interest coverage | – | -97.8× | – | |
| Inventory turnover | – | – | 10.5× | |
| Capex to revenue | – | 13.4% | 4.4% | |
| Diluted shares | – | 0M | 29M |
Where the cash went
Fiscal 2021 to 2025, five years combined
GeneDx generated $751.51M from operations and spent $46.31M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$751.51M
Used
$46.31M
Capital expenditure$46.31M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-4.9%
×Asset turnover0.91×
×Equity multiplier1.70×
=Return on equity, FY2025-7.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -4.9% | 0.91× | 1.70× | -7.6% |
| FY2024 | -17.1% | 0.73× | 1.77× | -22.1% |
| FY2023 | -86.8% | 0.45× | 1.89× | -73.0% |
| FY2022 | -233.9% | 0.45× | 1.63× | -171.1% |
| FY2021 | -115.6% | 0.53× | 13.88× | -845.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
6of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$21.02M
- Cash generatingOperating cash flow above zero$33.28M
- Return on assets improvedROA up on the prior year-12.5% → -5.0%
- Earnings backed by cashOperating cash flow above net income$33.28M vs -$21.02M
- Less leverageLong-term debt to assets fell12.4% → 9.2%
- Better liquidityCurrent ratio rose3.61 → 2.46
- No dilutionShare count did not rise27M → 29M
- Gross margin improvedGross margin up on the prior year63.64% → 69.74%
- More efficientAsset turnover rose0.73 → 1.02